Remdesivir (RDV, GS-5734) is a new antiviral drug in the nucleotide analog category. The U.S. Food and Drug Administration (FDA) reviewed the company's application for an investigational new drug (IND) for Remdesivir to treat Covid-19, and granted investigational new drug authorisation to study the drug in February 2020.
On Saturday (March 21), Trump lobbied for hydroxychloroquine and azithromycin, saying that hydroxychloroquine combined with azithromycin does have the opportunity to play a subversive role in the history of drugs to inhibit COVID-19.
A review was published in Nature Reviews Drug Discovery magazine, which explores treatment options for 2019-nCoV. The authors said that, given the urgency of the need for 2019-nCoV therapy, this article mainly focused on repurposing existing antiviral therapies for 2019-nCoV.
Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in individuals 12 years and older, who have been symptomatic for less than 24 hours.
At the beginning of 2020, the novel coronavirus (COVID-19) came furiously. The impact of this epidemic that has swept the country on the Chinese economy is unavoidable, but this will only be temporary. The fundamentals of the Chinese economy and the long-term positive trend will not be changed by this epidemic. We have the ability to minimize the impact of the epidemic on the economy. Now, let's learn more about the novel coronavirus (COVID-19).